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Editorial, page 1760
Association of metabolic syndrome and
change in Unified Parkinson’s Disease
Rating Scale scores
ABSTRACT
Objective: To explore the association between metabolic syndrome and the Unified Parkinson’s
Disease Rating Scale (UPDRS) scores and, secondarily, the Symbol Digit Modalities Test (SDMT).
Methods: This is a secondary analysis of data from 1,022 of 1,741 participants of the National
Institute of Neurological Disorders and Stroke Exploratory Clinical Trials in Parkinson Disease
Long-Term Study 1, a randomized, placebo-controlled trial of creatine. Participants were catego-
rized as having or not having metabolic syndrome on the basis of modified criteria from the
National Cholesterol Education Program Adult Treatment Panel III. Those who had the same met-
abolic syndrome status at consecutive annual visits were included. The change in UPDRS and
SDMT scores from randomization to 3 years was compared in participants with and without met-
abolic syndrome.
Results: Participants with metabolic syndrome (n 5 396) compared to those without (n 5 626)
were older (mean [SD] 63.9 [8.1] vs 59.9 [9.4] years; p , 0.0001), were more likely to be male
(75.3% vs 57.0%; p, 0.0001), and had a higher mean uric acid level (men 5.7 [1.3] vs 5.3 [1.1]
mg/dL, women 4.9 [1.3] vs 3.9 [0.9] mg/dL, p , 0.0001). Participants with metabolic syndrome
experienced an additional 0.6- (0.2) unit annual increase in total UPDRS (p5 0.02) and 0.5- (0.2)
unit increase in motor UPDRS (p 5 0.01) scores compared with participants without metabolic
syndrome. There was no difference in the change in SDMT scores.
Conclusions: Persons with Parkinson disease meeting modified criteria for metabolic syndrome
experienced a greater increase in total UPDRS scores over time, mainly as a result of increases
in motor scores, compared to those who did not. Further studies are needed to confirm this
finding.
ClinicalTrials.gov identifier: NCT00449865. Neurology® 2017;89:1789–1794
GLOSSARY
ATP III5 Adult Treatment Panel III; BMI 5 body mass index; NCEP5 National Cholesterol Education Program; NET-PD LS 1 5
National Institute of Neurological Disorders and Stroke Exploratory Trials in PD Long-Term Study 1; PD 5 Parkinson disease;
SDMT 5 Symbol Digit Modalities Test; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
Metabolic syndrome is a combination of conditions—hypertension, hyperglycemia, hyperlip-
idemia, and increased waist circumference—that, when occurring together, escalate a person’s
risk for heart disease, stroke, and diabetes mellitus. Recent studies suggest that the syndrome is
also associated with increased risk of other diseases,1–8 including Parkinson disease (PD).1,9
However, studies on the association of metabolic syndrome10 or its components,11–20 e.g.,
hyperglycemia or diabetes mellitus, and PD have yielded inconsistent results. For example, 2
recent meta-analyses of the association of diabetes mellitus and the risk of developing PD had
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opposite conclusions: one that diabetes melli-
tus increases the risk of PD21 and another that
it does not.22 Higher body mass index (BMI)
in midlife, i.e., .25 kg/m2, has been associ-
ated with an increased risk of PD in multiple
studies16,18,23 but not in others.19,24 A recent
study found that patients with PD with
increasing BMI had slower PD progression
than those with a stable or declining BMI25
as measured by the Unified Parkinson’s Dis-
ease Rating Scale (UPDRS). Another study
reported that diabetes mellitus was associated
with more rigidity and a parkinsonian-type
gait in aging persons without a diagnosis of
PD or dementia.26
To the best of our knowledge, the effect of
metabolic syndrome on PD progression has
not previously been studied. The aim of this
study was to investigate the relationship
between metabolic syndrome and progression
of PD using change in UPDRS. Because met-
abolic syndrome may have a role in driving
cognitive impairment in PD, we also explored
the association of metabolic syndrome and
a cognitive measure. Using data from the
National Institute of Neurological Disorders
and Stroke Exploratory Trials in PD Long-
Term Study 1 (NET-PD LS 1),27 we com-
pared the progression of PD in those who
had metabolic syndrome throughout the first
3 years of the trial to those who were without
evidence of metabolic syndrome.
METHODS Participants. NET-PD LS 1 was a large, multi-
center, placebo-controlled, randomized, double-blind trial of
10 mg creatine monohydrate vs placebo and was conducted from
March 2007 to September 2013. The study was terminated early,
when an interim analysis determined that creatine had no effect
on progression of PD.28 All participants had early-stage PD and
were on dopaminergic therapy at randomization. The study
design and characteristics of the population have been reported
previously.27
The NET-PD LS 1 study enrolled a total of 1,741 partici-
pants. Each participant was categorized as having metabolic syn-
drome or not at baseline and 1-, 2-, and 3-year visits. As a result of
missing data at any of these visits, we were unable to assess the
metabolic syndrome status of 319 participants. Furthermore,
only those who maintained the same metabolic syndrome status
for consecutive visits were included. Four hundred participants
experienced a change in their metabolic syndrome status during
the first 3 years of the study and were excluded from the analysis.
Therefore, of the 1,741 participants at baseline, 1,022 were
included in the final analysis.
Standard protocol approvals, registrations, and patient
consents. NET-PD LS 1 is registered on clinicaltrials.gov with
identifier NCT00449865. The institutional review boards of
each institution that participated approved the study, and all
participants signed informed consent.
Outcome measures. As part of NET-PD LS-1, UPDRS scores
for parts I, II, and III were assessed over time. Three outcome
measures were used for this study from baseline to the 3-year visit.
The primary outcome measure was the change in the total
UPDRS score (which we define here as parts I 1 II 1 III) from
the baseline (randomization) to the 3-year visit. The secondary
outcome measure was the change in the motor UPDRS (part III)
over the same time range. An additional outcome measure was the
Symbol Digit Modalities Test (SDMT) score,29 which was the
only cognitive test collected at annual visits.
Exposure. We categorized participants on the basis of the com-
monly agreed-on criteria from the National Cholesterol Educa-
tion Program (NCEP) Adult Treatment Panel III (ATP III),
which was updated in 2005.30 The NCEP criteria require 3 or
more of the following to be diagnosed with metabolic syndrome:
(1) waist circumference.35 in for women and.40 in for men,
(2) serum triglycerides$150 mg/dL (1.7 mmol/L) or medication
therapy for high triglycerides, (3) serum high-density lipoprotein
cholesterol,50 mg/dL (1.3 mmol/L) in women and,40 mg/dL
(1 mmol/L) in men or medication treatment for low high-density
lipoprotein cholesterol, (4) blood pressure $130/85 mm Hg or
on medication therapy for high blood pressure, and (5) fasting
plasma glucose $100 mg/dL (5.6 mmol/L) or on medication
therapy for high glucose.
Because the protocol for NET-PD LS 1 did not include waist
measurements or collection of cholesterol, triglyceride, or fasting
glucose levels, we adapted the ATP III criteria30 for use in our
study.30 Metabolic syndrome was defined as having 2 or more of
the following criteria: (1) BMI .30 kg/m2; (2) on statin medi-
cation; (3) systolic blood pressure .130 mm Hg, diastolic blood
pressure .85 mm Hg, or on antihypertensive medication; or (4)
random blood sugar.120 mg/dL or on antihyperglycemic med-
ication. Criteria were the same for both sexes. Participants who no
longer fulfilled our modified criteria at subsequent visits were
excluded from the analysis to avoid misclassification bias. Using
these modified ATP III criteria, participants were classified into 2
groups: participants who had metabolic syndrome throughout the
3 years of the study and participants who were without evidence
of metabolic syndrome across all 3 years.
Statistical methods. Descriptive statistics (mean, SD, fre-
quency, and percentages) were used to summarize the demo-
graphics for 2 groups: metabolic syndrome and no metabolic
syndrome. Differences in the mean or proportions between these
2 groups were checked by t test or x2 test.
The association of metabolic syndrome with the change in the
total and motor UPDRS and SDMT scores across time was esti-
mated with a linear mixed model. Because the randomization
process included blocking by site, both site and treatment assign-
ment (creatine vs placebo) were used as covariates.27
Metabolic syndrome, time in years, treatment group, and the
interaction term of metabolic syndrome and time in years were
tested in this model after adjustment for confounding variables:
baseline age, baseline total UPDRS, sex, handedness, race, uric
acid levels, and disease duration at baseline. Similarly, a second
model was adjusted for motor UPDRS score, and the only differ-
ence was the covariate baseline motor UPDRS instead of total
UPDRS score as stated before. A locally weighted scatterplot
smoothing plot for change in total UPDRS across time is pre-
sented to show the differences by group. The SDMT analysis,
using change in SDMT from baseline as the response variable,
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predictors of baseline SDMT, metabolic syndrome status, time in
years, and the interaction term of metabolic syndrome and time
in years, was adjusted for confounding variables of baseline age,
total UPDRS score, sex, handedness, race, uric acid levels, and
disease duration.
All statistical analyses were conducted with SAS statistical
software (version 9.4, SAS Institute Inc, Cary, NC).
Sensitivity analyses. We considered alternative ways of analyz-
ing the current dataset. We looked at the entire NET-PD LS1
cohort, dividing the metabolic vs no metabolic syndrome groups
according to their status at baseline, and followed them for their
entire participation in the study, up to 5 years, without regard to
whether they changed status at any annual visit. We also ran the
analyses with a stricter definition of metabolic syndrome, defining
metabolic syndrome as having 3 or more of the 4 criteria rather
than 2 or more as in the presented data. Furthermore, we ran the
analyses with different criteria for metabolic syndrome, consid-
ering that if participants were taking an antihypertensive, anti-
hyperlipidemia, or antihypergylcemic medication, they would not
meet that criterion for metabolic syndrome because the indication
was adequately treated. Each of these sensitivity analyses pro-
duced the same results. Because the results were the same as those
presented here, they are not shown, but they are available on
request from the authors.
RESULTS Table 1 shows the demographic character-
istics of the participants for this study according to
whether participants were categorized as having met-
abolic syndrome. Baseline mean age and mean uric
acid levels were significantly different in these 2
groups, as well as the proportion of men and women
in these 2 groups. Participants with metabolic syn-
drome were more likely to be men, to be older, and to
have a higher mean uric acid level compared to those
without metabolic syndrome.
Table 2 shows the change in total UPDRS over 3
years compared between the metabolic syndrome and
no metabolic syndrome groups. On average, partici-
pants without metabolic syndrome experienced a 1.7-
unit annual increase in total UPDRS score from their
baseline values, while participants with metabolic
syndrome experienced a 2.3- (1.71 0.6) unit annual
increase in total UPDRS change from baseline after
controlling for covariates. This information is also
presented in the figure, which demonstrates that par-
ticipants with metabolic syndrome were more likely
to have increases in total UPDRS scores, especially in
the third year of study.
Table 3 shows the change in motor UPDRS (part
III) score, the secondary outcome measure, over 3
years compared between the 2 groups. On average,
participants without metabolic syndrome experienced
a 0.8-unit annual increase in their motor UPDRS
score, while participants with metabolic syndrome
experienced a 1.3- (0.8 1 0.5) unit increase per year.
Table 4 shows the change in SDMT. While the
SDMT declined 0.2 units (standard error 5 0.1) per
year (p 5 0.03), there was no significant difference,
0.3- vs 0.2-unit annual decline, between those with vs
without metabolic syndrome (p5 0.77), respectively.
DISCUSSION This study shows that participants
with early-stage, treated PD who met modified cri-
teria for metabolic syndrome had more rapid pro-
gression as measured by both the total and motor
UPDRS scores over time compared to those without
metabolic syndrome. This finding is consistent with
prior studies suggesting that the presence of metabolic
syndrome is associated with increased risk of devel-
oping PD, Alzheimer disease, cognitive decline, and
other diseases.1–8 We could find no other study
Table 1 Baseline characteristics of participants (n 5 1,022) by metabolic
syndrome status
Demographics
No metabolic syndrome
(n 5 626), mean (SD)
Metabolic syndrome
(n 5 396), mean (SD) p Value
Age, y 59.9 (9.4) 63.9 (8.1) ,0.0001
Male, n (%) 357 (57.0) 298 (75.3) ,0.0001
Disease duration, y 1.6 (1.1) 1.6 (1.1) 0.92
Total UPDRS score 25.0 (10.7) 26.0 (10.7) 0.16
Motor UPDRS score 17.0 (7.9) 17.7 (7.9) 0.14
Treatment with creatine, n (%) 310 (49.5) 188 (47.5) 0.52
Handedness: right, n (%) 560 (89.5) 352 (88.9) 0.78
Handedness: left/mixed, n (%) 66 (10.5) 44 (11.1) 0.78
White race, n (%) 586 (93.6) 365 (92.2) 0.38
Uric acid, men, mg/dL 5.3 (1.1) 5.7 (1.3) ,0.0001
Uric acid, women, mg/dL 3.9 (0.9) 4.9 (1.3) ,0.0001
Abbreviation: UPDRS 5 Unified Parkinson’s Disease Rating Scale.
Table 2 Change in total UPDRS
Effects Estimate (SE) 95% CI p Value
Metabolic syndromea 20.6 (0.5) 21.6 to 0.5 0.30
Time, y 1.7 (0.2) 1.4 to 2.0 ,0.0001
Metabolic syndrome 3 time 0.6 (0.2) 0.1 to 1.0 0.02
Uric acid, mg/dL 0.2 (0.2) 20.1 to 0.5 0.29
Abbreviations: CI 5 confidence interval; SE 5 standard error; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
aMetabolic syndrome is a dichotomized variable. In the model, the reference group is participants without metabolic
syndrome. The site and treatment assignment (creatine vs placebo) were included as covariates.
Neurology 89 October 24, 2017 1791
showing an association between metabolic syndrome
and progression of PD, so this finding needs confir-
mation. If confirmed, this would raise the possibility
that improved treatment of metabolic syndrome
could offer a novel approach to slowing PD
progression.
How metabolic syndrome might accelerate PD
progression is not known. Because metabolic syn-
drome is a combination of conditions, each of these
conditions could contribute to the association. A
recent analysis of the NET-PD population found that
an increase in BMI was associated with a slower
increase in UPDRS scores, so it seems unlikely that
the high BMI component of metabolic syndrome
contributes strongly to the association of metabolic
syndrome and increasing UPDRS scores. Another
metabolic syndrome condition, hypertension, could
drive faster PD progression if it caused those affected
to have more CNS ischemia or strokes. Brain imaging
data were not collected in the NET-PD study, so this
theory cannot be substantiated with our data. Regard-
ing blood trigyceride,23 glucose,23,31 and high-density
lipoprotein cholesterol levels, the literature to date is
conflicting, lacking, or not informative. Insulin resis-
tance and inflammation underlie metabolic syn-
drome,32 and these pathologic mechanisms also
contribute to the progressive loss of dopaminergic
cells that results in PD.33,34 The association found
between metabolic syndrome and PD may therefore
be attributed to common pathophysiologic pathways.
The faster progression of motor signs in our partic-
ipants with metabolic syndrome compared to those
without could be related to the accumulating evi-
dence of brain abnormalities in the expression of insu-
lin and insulin growth factors and their related
receptors and CNS insulin resistance being reported
in PD. Activities of insulin growth factors include
support of neuronal growth and survival. Recent liter-
ature suggests that these insulin-related CNS abnor-
malities may increase sensitivity to neurotoxins and
the accumulation of a-synuclein.35,36 While further
studies are needed to judge whether these brain
abnormalities correlate with clinical longitudinal
signs, given that patients with PD have CNS
insulin-related abnormalities that normally play a pro-
tective role, concurrent metabolic syndrome is likely
to exacerbate these baseline abnormalities and to
enhance the progression of disease.
While uric acid levels are not a defined component
of metabolic syndrome, the syndrome is associated
with higher uric acid levels. Studies to date suggest that
higher uric acid levels are associated with more slowly
increasing UPDRS scores.37,38 In this study, however,
the metabolic syndrome group had higher uric acid
levels and had faster increasing UPDRS scores.
The association of metabolic syndrome and cogni-
tive function was explored in this study. In NET-PD,
the only cognitive measure captured at annual visits
was the SDMT score. There was no significant differ-
ence: 0.3- vs 0.2-unit annual decline in participants
with metabolic syndrome vs without (p 5 0.77).
However, this analysis was limited by the minimal
decline in SDMT scores that occurred in this early
treated PD group.39 Furthermore, the SDMT evalu-
ates attention and not other cognitive domains or
global cognitive function.40
A strength of this study is that it is derived from
a relatively large and well-characterized cohort. In
addition, the results of the sensitivity analyses consis-
tently generated the same result: those with metabolic
syndrome had greater increasing UPDRS scores over
time than those without metabolic syndrome. How-
ever the conclusions are limited by the use of a mod-
ified definition of metabolic syndrome. Therefore,
additional studies incorporating stricter measure-
ments of the components of metabolic syndrome
are required to confirm the findings of this initial
study.
Figure Locally weighted scatterplot smoothing plot for change in total UPDRS
Sample size: 1,022 (assuming that the duration of 1 month is 30.5 days). UPDRS 5 Unified
Parkinson’s Disease Rating Scale.
Table 3 Change in motor UPDRS
Effects Estimate (SE) 95% CI p Value
Metabolic syndrome 20.4 (0.4) 21.1 to 0.4 0.34
Time, y 0.8 (0.1) 0.6 to 1.0 ,0.0001
Metabolic syndrome 3 time 0.5 (0.2) 0.2 to 0.8 0.01
Uric acid, mg/dL 0.2 (0.1) 20.1 to 0.4 0.14
Abbreviations: CI 5 confidence interval; SE 5 standard error; UPDRS 5 Unified Parkinson’s
Disease Rating Scale.
1792 Neurology 89 October 24, 2017
In NET-PD LS1, participants meeting criteria for
metabolic syndrome experienced a greater increase in
total UPDRS scores, mainly due to increases in motor
scores, compared to those not meeting these criteria.
If confirmed, future work should determine whether
treatment of metabolic syndrome results in a slower
increase in UPDRS scores over time.
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